MethylGene Inc.
TSX : MYG

MethylGene Inc.

May 16, 2008 13:30 ET

Clinical Data for MethylGene's MGCD0103 to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting

One oral presentation and two posters for MGCD0103, an oral, isoform-selective HDAC inhibitor

MONTREAL, QUEBEC--(Marketwire - May 16, 2008) - MethylGene Inc. (TSX:MYG) today announced that data from MGCD0103 clinical trials will be presented in one oral and two poster presentations at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting which will be held from May 30 to June 3, 2008 in Chicago, Illinois.

At the conference, principal investigators involved in MGCD0103 clinical trials will disclose updated preliminary data from Trials 010, 008 and 006. The following are the session details:

Oral Presentation

Isotype-selective histone deacetylase (HDAC) inhibitor, MGCD0103, demonstrates clinical activity and safety in a Phase II trial in patients with relapsed/refractory classical Hodgkin lymphoma (Trial 010).


Abstract No. 8507
Presenter: R. Gregory Bociek, MD
Location: E354b
Time: Sunday, June 1 at 8:15 a.m. CDT


Poster Discussion

Treatment of relapsed or refractory non-Hodgkin lymphomas with the oral isotype-selective histone deacetylase inhibitor, MGCD0103: interim results from a Phase II study (Trial 008).



Abstract No. 8528
Presenter: Michael Crump, MD
Poster No. 3
Location: E450a
Time: Tuesday, June 3 during the 8:00 a.m. to 12:30 p.m. CDT session


Poster Presentation

Phase I/II: The oral isotype-selective HDAC inhibitor, MGD0103, in combination with gemcitabine in patients with refractory solid tumors (Trial 006).



Abstract No. 4625
Presenter : Herbert Hurwitz, MD
Poster No. 44E
Location: S Hall A1
Time: Monday, June 2 from 8:00 a.m. to 12:00 p.m. CDT


About MethylGene

MethylGene Inc. (TSX:MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral, isoform-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I, Phase I/II and Phase II combination trials with Vidaza®, Gemzar® and Taxotere®. MGCD265 is an oral, multi-targeted kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases and is in Phase I clinical trials for solid tumor cancers. In addition, MethylGene's preclinical programs include: MGCD290, an HDAC inhibitor in combination with azoles for fungal infections, a kinase inhibitor program for ocular diseases, and a sirtuin inhibitor program for cancer. MethylGene's development and commercialization partners include Celgene Corporation, Taiho Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd. and EnVivo Pharmaceuticals. Please visit our website at www.methylgene.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management of MethylGene, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond MethylGene's control. These risks and uncertainties could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Such results, performance or achievements include, but are not limited to, the timing and effects of regulatory action; the continuation of collaborations; the results of clinical trials; the timing of enrollment or completion of clinical trials; the success, efficacy or safety of MGCD0103, MGCD265 or MGCD290; the ability to scale up, formulate and manufacture sufficient GMP, clinical or commercialization quantities of MGCD0103, MGCD265 or MGCD290, and the relative success or the lack of success in developing and gaining regulatory approval and/or market acceptance for any compound or new product including MGCD0103, MGCD265 or MGCD290. Such risks include, but are not limited to, the impact of general economic conditions, economic conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which MethylGene does business, stock market volatility, fluctuations in costs, expectations with respect to our intellectual property position and our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, changes in the competitive landscape including changes in the standard of care for the various indications in which MethylGene is involved, and changes to the competitive environment due to consolidation, as well as other risks, which you are urged to read, as described in MethylGene's Annual Information Form for the fiscal year ending December 31, 2007, under the heading 'risk factors,', and all other documents filed by the Company that can be found at www.sedar.com. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this presentation. These statements speak only as an update on the date they are made and MethylGene is under no obligation to revise such statements as a result of any event, circumstance or otherwise except in accordance with law.

Contact Information